Stoke Therapeutics, Inc. (STOK) Stock Price & Analysis
Stoke Therapeutics, Inc. (STOK) rose 1.28% to USD 29.37 as of June 10, 2026 at 00:47 UTC, according to Nexqual real-time market data.
STOK last closed at USD 29; the session ranged USD 28.57–30.06 on volume of 362,641 shares. Market capitalization is $1.83B, with a 52-week range of USD 11.12–40.22 (NMS). Source: Nexqual, June 10, 2026 at 00:47 UTC.
Key Statistics (as of June 10, 2026 at 00:47 UTC)
| Price | USD 29.37 |
|---|---|
| Change | ▲ 1.28% (up) |
| Previous Close | USD 29 |
| Open | USD 29.45 |
| Day Range | USD 28.57 – 30.06 |
| 52-Week Range | USD 11.12 – 40.22 |
| Volume | 362,641 shares |
| Market Cap | $1.83B |
| Exchange | NMS |
Technical Analysis (STOK)
Nexqual's technical model rates STOK "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:47 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.24 (neutral) |
| vs SMA50 | Below (USD 32.52) |
| MACD | -0.87 (negative) |
Analyst Ratings (STOK)
Wall Street analysts rate STOK "Strong Buy" based on 10 analysts, with a mean price target of USD 45.1 (range USD 35–60), per Nexqual as of June 10, 2026 at 00:47 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 45.1 |
| High Target | USD 60 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 12 / 0 / 0 |
Earnings (STOK)
| Next Earnings Date | 2026-05-07 |
|---|---|
| EPS Estimate | USD -0.76 |
| Revenue Estimate | $5.35M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.79 vs est -0.82 ▲ beat |
| 2025-12-31 | USD -0.97 vs est -0.74 ▼ miss |
| 2025-09-30 | USD -0.65 vs est -0.57 ▼ miss |
| 2025-06-30 | USD -0.4 vs est -0.54 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:47 UTC.
Financials & Fundamentals (STOK)
| Total Revenue | $32.08M |
|---|---|
| Revenue Growth (YoY) | -96.10% |
| Gross Margin | +100.00% |
| Operating Margin | -857.57% |
| Profit Margin | +0.00% |
| ROE | -45.58% |
| Debt / Equity | 0.87 |
| Current Ratio | 8.99 |
| Total Cash | $343.54M |
| Total Debt | $3.42M |
| Free Cash Flow | $-88.69M |
Source: Nexqual, June 10, 2026 at 00:47 UTC.
Financial Health Score (STOK)
Nexqual rates Stoke Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:47 UTC.
| Growth | Strong — Revenue +405% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $344M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$89M, burning cash |
| Efficiency | Critical — ROE -46%, ROA -27.2% |
Ownership (STOK)
| Insider Ownership | +3.82% |
|---|---|
| Institutional Ownership | +120.30% |
| Shares Outstanding | 62.28M |
| Float | 46.76M |
| Short % of Float | +18.75% |
Source: Nexqual, June 10, 2026 at 00:47 UTC.
Leadership (STOK)
Stoke Therapeutics, Inc. is led by Ian F. Smith A.C.A., C.P.A. (age 59), CEO & Director, per Nexqual as of June 10, 2026 at 00:47 UTC.
| CEO & Director | Ian F. Smith A.C.A., C.P.A. (age 59) |
|---|---|
| Co-Founder & Independent Director | Adrian R. Krainer (age 66) |
| Chief Financial Officer | Thomas Edward Leggett (age 48) |
| Advisor & Director | Edward M. Kaye (age 76) |
| Director of Communications & Investor Relations | Doug Snow |
Major Backers & Investors (STOK)
Notable institutional backers of Stoke Therapeutics, Inc. include RTW Investments LP, FMR, LLC, Lynx1 Capital Management Lp, according to Nexqual as of June 10, 2026 at 00:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 9.03% |
| FMR, LLC | 8.64% |
| Lynx1 Capital Management Lp | 7.65% |
| Redmile Group, LLC | 6.69% |
| Morgan Stanley | 5.5% |
| Baker Bros. Advisors, LP | 5.36% |
| Toronto Dominion Bank | 5.1% |
| Wellington Management | 4.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.27% |
Source: Nexqual, June 10, 2026 at 00:47 UTC.
From Stoke Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
- The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
- Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.
- The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
| GOSS | Gossamer Bio, Inc. | USD 0.16 | ▼ 8.57% |
| PHAT | Phathom Pharmaceuticals, Inc. | USD 9.82 | ▼ 3.06% |
| SRRK | Scholar Rock Holding Corporatio | USD 45.58 | ▲ 2.89% |
| BDTX | Black Diamond Therapeutics, Inc | USD 1.9 | ▼ 3.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:47 UTC. This page is informational and not investment advice.